Histology-tailored neoadjuvant chemotherapy failed to show superiority compared with standard neoadjuvant chemotherapy in patients with high-risk STS.
Findings seen among patients <40 years with bone or soft tissue sarcomas, regardless of disease stage.
An analysis of how functional outcomes are measured in patients with soft tissue sarcoma revealed the efficacy of salvage surgery, and a need to improve frequency of FO measurements.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pomalyst (pomalidomide; Celgene) for the treatment of patients with Kaposi sarcoma.
[OncoTargets and Therapy] This review addresses common questions facing the clinician and patient, and provide an update on new strategies for Ewing Sarcoma therapy.
Two cases studies demonstrate whether crushed pazopanib is a feasible alternative for patients who cannot swallow the tablets whole.
A retrospective review revealed the association between tumor location, disease histology, and prognosis for patients with primary cardiac sarcoma.
Antiretroviral therapy has led to a dramatic reduction in incidence of AIDS-related Kaposi sarcoma; however, changes in the disease may lead to a resurgence in its risk for people with HIV infection.
[Cancer Management and Research] The prognostic values of overall survival and cancer-specific survival for bone sarcomas of the hands or feet were assessed using Cox proportional hazards regression model with univariate and multivariate analyses.
With median age of participants in clinical trials for soft-tissue sarcoma younger than most patients who develop the disease, these researchers sought to determine the prevalence of including persons older than 65 in clinical trials and the efficacy of first-line chemotherapy for STS in older patients.
Please login or register first to view this content.
